Suchergebnisse

The Institute of Medicine: Adviser to the Nation -- Highlighted reports -- Global health and infectious disease -- Health sciences and the research enterprise -- Ensuring food safety and proper nutrition -- Assuring the public's health -- Health care delivery system and performance capabilities -- Human security and bioterrorism -- Military personnel and veterans -- Robert Wood Johnson Health Policy Fellowships Program -- Senior nurse scholar program -- Recent and upcoming reports

FrontMatter -- Reviewers -- Acknowledgments -- Contents -- Tables, Figures, and Boxes -- 1 Introduction -- 2 FDA Safe Use Initiative -- 3 Over-the-Counter Products -- 4 Initiatives to Advance Patient-Centered Drug Safety -- 5 Identifying Activities Around Which to Build Partnerships for Patient-Centered Drug Safety -- 6 How Can the Lessons of Health Literacy Be Used to Build Patient-Centered Outcomes for Safe Use? -- References -- Appendix A: Acronyms -- Appendix B: Workshop Agenda -- Appendix C: Workshop Speaker Biosketches.

"Every year, public and private funders spend many billions of dollars on large-scale, complex, multi-national health initiatives. The only way to know whether these initiatives are achieving their objectives is through evaluations that examine the links between program activities and desired outcomes. Investments in such evaluations, which, like the initiatives being evaluated, are carried out in some of the world's most challenging settings, are a relatively new phenomenon. In the last five years, evaluations have been conducted to determine the effects of some of the world's largest and most complex multi-national health initiatives. Evaluation Design for Complex Global Initiatives is the summary of a workshop convened by the Institute of Medicine in January 2014 to explore these recent evaluation experiences and to consider the lessons learned from how these evaluations were designed, carried out, and used. The workshop brought together more than 100 evaluators, researchers in the field of evaluation science, staff involved in implementing large-scale health programs, local stakeholders in the countries where the initiatives are carried out, policy makers involved in the initiatives, representatives of donor organizations, and others to derive lessons learned from past large-scale evaluations and to discuss how to apply these lessons to future evaluations. This report discusses transferable insights gained across the spectrum of choosing the evaluator, framing the evaluation, designing the evaluation, gathering and analyzing data, synthesizing findings and recommendations, and communicating key messages. The report also explores the relative benefits and limitations of different quantitative and qualitative approaches within the mixed methods designs used for these complex and costly evaluations"--Publisher's description.

"The U.S. Environmental Protection Agency (EPA) is one of several federal agencies responsible for protecting Americans against significant risks to human health and the environment. As part of that mission, EPA estimates the nature, magnitude, and likelihood of risks to human health and the environment; identifies the potential regulatory actions that will mitigate those risks and protect public health1 and the environment; and uses that information to decide on appropriate regulatory action. Uncertainties, both qualitative and quantitative, in the data and analyses on which these decisions are based enter into the process at each step. As a result, the informed identification and use of the uncertainties inherent in the process is an essential feature of environmental decision making. EPA requested that the Institute of Medicine (IOM) convene a committee to provide guidance to its decision makers and their partners in states and localities on approaches to managing risk in different contexts when uncertainty is present. It also sought guidance on how information on uncertainty should be presented to help risk managers make sound decisions and to increase transparency in its communications with the public about those decisions. Given that its charge is not limited to human health risk assessment and includes broad questions about managing risks and decision making, in this report the committee examines the analysis of uncertainty in those other areas in addition to human health risks. Environmental Decisions in the Face of Uncertainty explains the statement of task and summarizes the findings of the committee."--Publisher's description